

filed August 21, 1997.

now U.S. Pat No. 6,271,89 B1

In the Claims

Please cancel all claims and add the following new claims.

13. ~~22~~. A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, ~~(a pharmaceutical composition comprising a compound selected from the group consisting of GLP-1, GLP-1 analogs, and GLP-1 derivatives, a buffer, and a preservative at a dose effective to normalize blood glucose.~~
14. ~~23~~. A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a compound selected from the group consisting of GLP-1, GLP-1 analogs, and GLP-1 derivatives, wherein the administration occurs within the first 72 hours following a myocardial infarction.
15. ~~24~~. A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a GLP-1 derivative at a dose effective to normalize blood glucose.
16. ~~25~~. The method of Claim ~~24~~<sup>15</sup>, wherein the GLP-1 derivative is a GLP-1 analog having an acylated lysine  $\epsilon$ -amino group.
17. ~~26~~. The method of Claim ~~22~~<sup>13</sup>, wherein the compound is complexed with a divalent metal cation.
18. ~~27~~. The method of Claim ~~22~~<sup>13</sup>, wherein the preservative is selected from the group consisting of meta-cresol and phenol.